X4 PHARMACEUTICALS, INC Revenue from Contract with Customer, Excluding Assessed Tax
X4 PHARMACEUTICALS, INC (XFOR) reported Revenue from Contract with Customer, Excluding Assessed Tax of $8.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $8.81M, a 346.33% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.71M, a 90.60% decline year-over-year.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $2.57M, a 79.08% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.76M, a 215.18% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $35.11M, a 1273.21% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.56M.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.81M 10-Q · filed 2026-08-06 | $11.51M 10-Q · filed 2026-08-06 | $14.08M derived: sum of 3 quarters · filed 2026-08-06 | $15.85M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.71M 10-Q · filed 2026-05-06 | $5.28M derived: sum of 2 quarters · filed 2026-05-06 | $7.04M derived: sum of 3 quarters · filed 2026-05-06 | $9.01M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.33M derived: sum of 2 quarters · filed 2026-03-17 | $6.31M derived: sum of 3 quarters · filed 2026-08-06 | $35.11M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $1.76M 10-Q · filed 2025-11-05 | $3.74M derived: sum of 2 quarters · filed 2026-08-06 | $32.55M 10-Q · filed 2025-11-05 | $33.98M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $1.97M 10-Q · filed 2026-08-06 | $30.78M 10-Q · filed 2026-08-06 | $32.21M derived: sum of 3 quarters · filed 2026-08-06 | $32.77M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $28.81M 10-Q · filed 2026-05-06 | $30.24M derived: sum of 2 quarters · filed 2026-05-06 | $30.80M derived: sum of 3 quarters · filed 2026-05-06 | $31.36M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.99M derived: sum of 2 quarters · filed 2026-03-17 | $2.56M derived: sum of 3 quarters · filed 2026-03-17 | $2.56M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $560.00K 10-Q · filed 2025-11-05 | $1.12M derived: sum of 2 quarters · filed 2025-11-05 | $1.12M 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $563.00K 10-Q · filed 2025-08-08 | $700.00K 10-Q · filed 2024-08-08 | $563.00K 10-Q · filed 2025-08-08 | $700.00K 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | ||||||
| 2023-12-31 | $0.00 10-K · filed 2026-03-17 | ||||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $0.00 10-K · filed 2023-03-21 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-03 | $0.00 10-Q · filed 2021-08-03 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $0.00 derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $0.00 derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 derived: sum of 3 quarters · filed 2023-03-21 | $3.00M 10-K · filed 2023-03-21 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $3.00M 10-Q · filed 2021-11-04 | $3.00M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-03 | $3.00M 10-Q · filed 2021-08-03 | $3.00M derived: sum of 3 quarters · filed 2022-03-17 | $3.00M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-06 | $3.00M derived: sum of 2 quarters · filed 2022-03-17 | $3.00M derived: sum of 3 quarters · filed 2022-03-17 | $3.00M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $3.50M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | $3.50M derived: sum of 3 quarters · filed 2020-08-04 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $3.50M derived: sum of 2 quarters · filed 2020-05-07 | |||||
| 2018-12-31 | $3.50M 10-K · filed 2019-03-11 | $0.00 10-K · filed 2021-03-19 | $3.50M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |